Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire August 23, 2019

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire August 22, 2019

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Myriad Genetics, Inc. (MYGN)

Press Releases August 22, 2019

Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. (NASDAQ: MYGN) on Behalf of Stockholders and Encourages Myriad Investors to Contact the Firm

PR Newswire August 22, 2019

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention

GlobeNewswire August 22, 2019

MYGN Loss Alert: Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations

GlobeNewswire August 21, 2019

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire August 21, 2019

SHAREHOLDER ALERT: Investigation of Myriad Genetics Announced by Holzer & Holzer, LLC

Business Wire August 21, 2019

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Myriad Genetics, Inc. - MYGN

Business Wire August 20, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Myriad Genetics, Inc. - MYGN

GlobeNewswire August 20, 2019

Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm

PR Newswire August 19, 2019

Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc.

PR Newswire August 16, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Myriad Genetics, Inc. - MYGN

GlobeNewswire August 14, 2019

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

GlobeNewswire August 13, 2019

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

GlobeNewswire August 7, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

GlobeNewswire August 6, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

GlobeNewswire June 27, 2019

Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

GlobeNewswire June 25, 2019

Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan

GlobeNewswire June 19, 2019

Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

GlobeNewswire June 5, 2019
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested